ArticleCanadian family physician Medecin de famille canadien2019
Quality of primary care among individuals receiving treatment for opioid use disorder.
Article in Canadian family physician Medecin de famille canadien, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Examining Access to Primary Care for People With Opioid Use Disorder in Ontario, Canada: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Chronic Disease Management Among People Treated for Comorbid Serious Mental Illness and/or Substance Use Disorders: A Population-Based Observational Study.Community mental health journal · 2026Article
- Reducing stigma in primary care toward people who use drugs: A pilot study exploring the promise and limits of stigma training.Journal of substance use and addiction treatment · 2025Article
- Safer Opioid Supply programs: Hydromorphone prescribing in Ontario as a harm reduction intervention to combat the drug poisoning crisis.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Perceptions of structural and provider-based substance use stigma interventions among primary care professionals.Drug and alcohol dependence reports · 2024Article
- Barriers to and facilitators of screening for cervical and breast cancer: Experiences of non-adherent women with current or previous drug use.Preventive medicine reports · 2024Article
- An environmental scan of residential treatment service provision in Ontario.Substance abuse treatment, prevention, and policy · 2023Article
- Screening for breast and cervical cancer among OST patients: a qualitative study of barriers and suggested interventions to increase participation.International journal of qualitative studies on health and well-being · 2023Article
- Amphetamine-Related Emergency Department Visits in Ontario, Canada, 2003-2020.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Article
- Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study.Harm reduction journal · 2023Article
- Participation in screening for breast and cervical cancer among women with current or previous drug use: a survey study.BMC public health · 2023Article
- Healthcare utilization for somatic conditions among Swedish patients in opioid substitution treatment, with and without on-site primary healthcare.BMC health services research · 2022Article
- Healthcare seeking among Swedish patients in opioid substitution treatment - a mixed methods study on barriers and facilitators.Substance abuse treatment, prevention, and policy · 2022Article
- Drug use disorder and risk of incident and fatal prostate cancer among Swedish men: a nationwide epidemiological study.Cancer causes & control : CCC · 2022Article
- Cohort study of team-based care among marginalized people who use drugs in Ottawa.Canadian family physician Medecin de famille canadien · 2022Article
- Cervical cancer screening, abnormal results, and follow-up in women with substance use-related diagnoses.Substance abuse · 2022Article
- Perceived healthcare stigma among patients in opioid substitution treatment: a qualitative study.Substance abuse treatment, prevention, and policy · 2021Article
- Healthcare Contacts Regarding Circulatory Conditions among Swedish Patients in Opioid Substitution Treatment, with and without On-Site Primary Healthcare.International journal of environmental research and public health · 2021Article
- Quality of Preventive and Chronic Illness Care for Insured Adults With Opioid Use Disorder.JAMA network open · 2021Article
- Drug use disorder and risk of incident and fatal breast cancer: a nationwide epidemiological study.Breast cancer research and treatment · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine if people receiving opioid agonist treatment (OAT), a long-term treatment approach, are also receiving high-quality primary care.
designRetrospective cohort study.
settingOntario.
participantsRecipients of public drug benefits who had at least 6 months of continuous use of methadone or buprenorphine between October 1, 2012, and September 30, 2013.
main outcome measuresRates of cancer screening and diabetes monitoring among those who had at least 6 months of continuous OAT were compared with matched controls. Conditional logistic regression models were used to assess differences after adjusting for confounders. In secondary analyses, outcomes by type of OAT and factors related to health care delivery were compared.
resultsA cohort of 20 406 OAT patients was identified; they had a mean (SD) of 31 (15) physician clinic visits during the 6-month study period. Compared with the control group, OAT patients were less likely to receive screening for cervical cancer (48.7% vs 62.6%; adjusted odds ratio [AOR] of 0.34, 95% CI 0.31 to 0.36), breast cancer (23.3% vs 49.1%; AOR = 0.19, 95% CI 0.16 to 0.24), and colorectal cancer (32.5% vs 49.0%; AOR = 0.34, 95% CI 0.30 to 0.38), and less likely to have monitoring for diabetes (11.7% vs 28.5%; AOR = 0.16, 95% CI 0.13 to 0.21). Patients receiving OAT who were taking buprenorphine, enrolled in a medical home, or seeing a low-volume prescriber were generally more likely to receive cancer screening and diabetes monitoring.
conclusionPatients receiving OAT were less likely to receive chronic disease prevention and management than matched controls were despite frequent health care visits, indicating a gap in equitable access to primary care.
Indexed as
Identifiers
31088874PMC6516690W2945003088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.